tradingkey.logo
tradingkey.logo
Search

Mesoblast Ltd

MESO
Add to Watchlist
13.270USD
+0.170+1.30%
Close 11-13 16:00(ET)
1.72BMarket Cap
LossP/E TTM

About Mesoblast Ltd Company

Mesoblast Limited is an Australia-based company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company’s Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: chronic heart failure (chf) and chronic low back pain (clbp) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.

Mesoblast Ltd Profile

Ticker SymbolMESO
Company nameMesoblast Ltd
IPO dateDec 16, 2004
CEOItescu (Silviu)
Number of employees81
Security typeDepository Receipt
Fiscal year-endDec 16
AddressL 38 55 Collins St
CityMELBOURNE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryAustralia
Postal code3000
Phone61396396036
Websitehttps://www.mesoblast.com/
Ticker SymbolMESO
IPO dateDec 16, 2004
CEOItescu (Silviu)

Company Executives of Mesoblast Ltd

Name
Name/Position
Position
Shareholding
Change
Dr. Silviu Itescu
Dr. Silviu Itescu
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
67.76M
--
Mr. Michael Schuster
Mr. Michael Schuster
Pharma Partnering
Pharma Partnering
--
--
Mr. Marcelo Santoro
Mr. Marcelo Santoro
Chief Commercial Officer
Chief Commercial Officer
--
--
Dr. Teresa Montagut
Dr. Teresa Montagut
Head - Clinical Development and Medical Affairs
Head - Clinical Development and Medical Affairs
--
--
Mr. James M. O'Brien
Mr. James M. O'Brien
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Lyn Cobley
Ms. Lyn Cobley
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Gregory George, M.D., Ph.D.
Dr. Gregory George, M.D., Ph.D.
Non-Executive Non-Independent Director
Non-Executive Non-Independent Director
--
--
Dr. Fiona See, Ph.D.
Dr. Fiona See, Ph.D.
Senior Vice President, Head - Translational Research
Senior Vice President, Head - Translational Research
--
--
Mrs. Jane Bell
Mrs. Jane Bell
Non-Executive Director
Non-Executive Director
--
--
Mr. Paul Hughes
Mr. Paul Hughes
Joint Company Secretary
Joint Company Secretary
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Silviu Itescu
Dr. Silviu Itescu
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
67.76M
--
Mr. Michael Schuster
Mr. Michael Schuster
Pharma Partnering
Pharma Partnering
--
--
Mr. Marcelo Santoro
Mr. Marcelo Santoro
Chief Commercial Officer
Chief Commercial Officer
--
--
Dr. Teresa Montagut
Dr. Teresa Montagut
Head - Clinical Development and Medical Affairs
Head - Clinical Development and Medical Affairs
--
--
Mr. James M. O'Brien
Mr. James M. O'Brien
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Lyn Cobley
Ms. Lyn Cobley
Non-Executive Independent Director
Non-Executive Independent Director
--
--

FAQs

Who are the top five shareholders of Mesoblast Ltd?

The top five shareholders of Mesoblast Ltd are: Dr. Silviu Itescu

How many institutions hold shares of Mesoblast Ltd (MESO)?

As of 2026Q1, 144 institutions hold shares of Mesoblast Ltd, with a combined market value of approximately 3.95M, accounting for 3.06% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -909190.00.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.